The EMPA-REG OUTCOME trial was the first CVOT to demonstrate efficacy as well as safety of an SGLT2 inhibitor for major adverse cardiovascular events in type 2 diabetes. Here, SLC5A2 is linked to type 2 diabetes mellitus.